终于有国产CAR-T企业快要扭亏了！传奇生物预计今年实现盈利

Core Insights - Legend Biotech's CAR-T therapy, Carvykti, is projected to generate $1.888 billion in revenue by 2025, marking a 95.9% increase from $963 million in the previous year [1] - The therapy has treated over 10,000 patients and has the largest cell therapy production facility in the U.S. [1] - The company expects Carvykti to become profitable in the fiscal year 2025 and overall profitability by 2026 [1] Market Expansion - By 2025, Carvykti will be available in over 279 treatment centers across 14 global markets, with the majority of revenue coming from the U.S. market, projected at $1.493 billion [2] - In the U.S., Carvykti's revenue is expected to account for nearly 80% of total income, benefiting from increased penetration in community healthcare and outpatient channels [2] - Although Carvykti is approved in China, it has not yet commenced commercial sales in that market, and its pricing in the U.S. is significantly higher than in China [2]